title: Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia.
abstract: Intravenous rasburicase (Elitek, Fasturtec) is the first recombinant uricolytic agent. It is indicated for the management of anticancer therapy-induced hyperuricaemia in paediatric patients in the EU and US, and in adult patients in the EU. Rasburicase is effective and generally well tolerated in adult and paediatric patients with, or at risk of developing, anticancer therapy-induced hyperuricaemia. It is associated with potentially serious haematological adverse events and hypersensitivity reactions, which must be considered prior to and during administration; rasburicase is contraindicated in patients predisposed to haemolysis or methaemoglobinaemia and in patients with glucose-6-phosphate dehydrogenase deficiency. Unlike allopurinol, rasburicase acts on existing uric acid concentrations. Rasburicase treatment resulted in significantly less systemic exposure to uric acid and a quicker therapeutic response than allopurinol in paediatric patients; further studies are needed to determine the comparative efficacy and tolerability of rasburicase versus allopurinol in adult patients. Although further pharmacoeconomic data would be useful, rasburicase was most cost effective for the prevention of hyperuricaemia in children and for treatment of this condition in adults. Thus, rasburicase is a useful option for the prophylaxis or treatment of anticancer therapy-induced hyperuricaemia in both adult and paediatric patients.
authors.affiliation: Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Vicki
authors.initials: V
authors.lastname: Oldfield
authors.forename: Caroline M
authors.initials: CM
authors.lastname: Perry
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D006074:Gout Suppressants / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D033461:Hyperuricemia / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D014503:Urate Oxidase / Q000009:adverse effects / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D006074:Gout Suppressants; C469709:rasburicase; D014503:Urate Oxidase